Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence

To the Editor: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 25% of the global population [1]. Despite its profound public health burden, only one pharmacological therapy, resmetirom, has received US Food and Drug Administration (FDA) approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis [2]. Lifestyle modifications remain the cornerstone of MASLD management; however, achieving and maintaining adequate weight loss is challenging for most individuals, underscoring the need for effective medical interventions.